- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Targeted Protein Degradation Market Size, Share | CAGR of 21.0%
Global Targeted Protein Degradation Market Size, Share, Analysis By Technology (PROTACs, Molecular Glues, LYTACs), By Therapeutic Area (Oncology, Neurological, Autoimmune Diseases), By Application (Drug Discovery, Clinical Therapeutics, Research) Region, Key Players – Dynamics, Ubiquitin-Proteasome System Modulators & Induced Proximity Biotech Pipelines & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026–2034) | Largest Region (2025) |
| USD 1.00 Billion | USD 5.56 Billion | 21.0% | North America, 44.0% |
The Targeted Protein Degradation Market was valued at approximately USD 0.83 billion in 2024 and reached USD 1.00 billion in 2025. The market is projected to grow to USD 5.56 billion by 2034, expanding at a CAGR of 21.0% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 4.56 billion over the analysis period. The market crossed its most significant regulatory milestone in a decade when, on May 1, 2026, the U.S. Food and Drug Administration approved VEPPANU (vepdegestrant)—developed by Arvinas, Inc. and Pfizer Inc.—as the world's first approved proteolysis-targeting chimera (PROTAC), fundamentally validating targeted protein degradation as a commercially viable therapeutic modality. Concurrently, Bristol-Myers Squibb's iberdomide NDA for relapsed/refractory multiple myeloma was accepted by the FDA in February 2026 with a PDUFA date of August 17, 2026, positioning the first cereblon E3 ligase modulator (CELMoD) approval as the sector's next binary catalyst.
Targeted Protein Degradation Market Global Forecast to 2034 (USD)
CAGR OF
21.0%
Targeted Protein Degradation Market
Get more details on this report -
Targeted protein degradation (TPD) is a paradigm-shifting drug discovery approach that exploits the cell's intrinsic protein disposal machinery—principally the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway—to selectively eliminate disease-causing proteins rather than merely inhibiting their activity. This mechanistic distinction enables TPD agents to address proteins without well-defined active sites, including transcription factors, scaffolding proteins, and disordered proteins, expanding the druggable proteome from approximately 3,000 historically targetable proteins to potentially 20,000 human proteins. Three principal TPD technology classes define the market: PROTACs (Proteolysis-Targeting Chimeras), heterobifunctional molecules with a target warhead and an E3 ligase recruiter connected by a chemical linker; molecular glue degraders (MGDs), monovalent small molecules that stabilize novel protein-protein interactions between a target and an E3 ligase to trigger degradation; and lysosome-targeting chimeras (LYTACs), which redirect extracellular or membrane proteins to the lysosomal pathway rather than the proteasome.
The market's acceleration is driven by three converging forces. The rising global cancer burden—the WHO recorded approximately 20 million new cancer diagnoses in 2022 with 9.7 million cancer-related deaths—creates the primary patient demand for novel mechanisms that can overcome resistance to conventional oncology drugs. The therapeutic case for TPD is particularly compelling in cancers where mutant or overexpressed proteins drive resistance to existing inhibitors: vepdegestrant targets the estrogen receptor in ESR1-mutated breast cancer where CDK4/6 inhibitor-pretreated patients have exhausted first-line options, while iberdomide targets IMiD-resistant multiple myeloma where cereblon binding affinity determines drug efficacy. The second force is the collapse of the ‘undruggable’ concept: PROTACs can degrade proteins including full-length androgen receptor splice variants (AR-V7), MYC oncoproteins, and BCL6 transcription factors that lack druggable catalytic pockets, opening oncology indications that conventional small molecules cannot address.
Strategic capital deployment by major pharmaceutical companies validates TPD's commercial potential at scale. In April 2024, Novartis paid Arvinas USD 150 million upfront and committed up to USD 1.01 billion in milestone payments for global rights to ARV-766 (androgen receptor PROTAC). In June 2025, Gilead Sciences entered a CDK2 molecular glue degrader option/license agreement with Kymera Therapeutics valued at up to USD 750 million. Earlier in 2024, Neomorph secured approximately USD 1.46 billion from Novo Nordisk, and VantAI received USD 674 million from Bristol-Myers Squibb, both for molecular glue degrader programs. These transactions collectively confirm that TPD has transitioned from academic novelty to industrial pharmaceutical priority, with deal values exceeding those of most first-generation small molecule innovation platforms.
North America dominated the targeted protein degradation market in 2025 with a 44.0% revenue share valued at approximately USD 440 million, anchored by the United States' concentration of TPD-focused biotechnology companies, National Institutes of Health funding, and the FDA's active engagement with TPD regulatory science. Approximately 80 companies globally were developing TPD technologies as of 2025, with the highest density in the United States. Europe is the fastest-growing region on an absolute deal-value basis, while Asia Pacific—led by Chinese domestic biotechs advancing PROTAC candidates into clinical trials—is the fastest-growing region by clinical trial count increase.
Market Definition & Scope
The targeted protein degradation market is defined as the commercial and clinical-stage market for small molecules and bifunctional agents that selectively eliminate disease-causing proteins by harnessing intracellular protein degradation pathways, including the ubiquitin-proteasome system (UPS) and the autophagy-lysosome pathway. The market encompasses four principal technology classes: PROTACs (Proteolysis-Targeting Chimeras), heterobifunctional molecules of approximately 700–1,200 Daltons composed of a target protein warhead, an E3 ubiquitin ligase recruiter, and a connecting chemical linker; molecular glue degraders (MGDs), monovalent small molecules of less than 500 Daltons that stabilize normally absent protein-protein interactions between a target protein and an E3 ligase to redirect target ubiquitination; LYTACs (Lysosome-Targeting Chimeras), bifunctional molecules directing extracellular or membrane proteins to lysosomal degradation via mannose-6-phosphate receptor engagement; AUTACs (AUtophagy-TArgeting Chimeras) for cytoplasmic cargo; and CELMoD (Cereblon E3 Ligase Modulator) agents, next-generation molecular glues specifically engineered for enhanced cereblon binding and deeper substrate degradation. Also included are selectiverly degrading variants of immunomodulatory drug (IMiD) scaffolds—specifically next-generation agents including iberdomide, mezigdomide, and golcadomide—and selective estrogen receptor degraders (SERDs) such as elacestrant (Orserdu) and the PROTAC-based estrogen receptor degrader vepdegestrant (VEPPANU).
This analysis covers targeted protein degradation technologies in approved commercial use, regulatory review (NDA/BLA), and active Phase 1–3 clinical development, as well as the platform technologies enabling their discovery including structure-based PROTAC design, AI-assisted molecular glue identification platforms, DNA-encoded library screening for E3 ligase binder discovery, and quantitative chemoproteomics. Explicitly excluded from this scope are classical thalidomide and first-generation lenalidomide/pomalidomide commercial revenues (which represent a distinct and genericized market segment), conventional small molecule inhibitors without protein degradation activity, and non-therapeutic research use-only TPD tools. The targeted protein degradation market represents a distinct segment within the broader precision oncology and drug discovery platform landscape, sharing characteristics with both the advanced therapeutics market (high value, specialty indications) and the platform technology market (enabling downstream drug development).
Key Takeaways
- Market Growth: The global targeted protein degradation market expanded from approximately USD 0.21 billion in 2020 to USD 1.00 billion in 2025 and is forecast to reach USD 5.56 billion by 2034, a 21.0% CAGR driven by the first PROTAC regulatory approval and the approaching first CELMoD approval, which together will trigger a commercial phase that was previously entirely clinical-stage for PROTAC and next-generation molecular glue platforms.
- Segment Dominance (Type): PROTACs held the largest technology type share at approximately 47.7–49.0% of market revenue in 2024, generating approximately USD 258–265 million, because PROTACs entered clinical trials earlier than other TPD modalities and because vepdegestrant—now FDA-approved as VEPPANU—is the most advanced commercial product in the PROTAC class.
- Segment Dominance (Therapeutic Area): Oncology accounted for approximately 61.4% of TPD market revenue in 2024 at approximately USD 332 million, driven by the mature breast cancer and multiple myeloma clinical pipelines and the regulatory precedent established by SERDs and IMiD-derived CELMoDs in hormone-driven and hematological malignancies.
- Driver: The expanding ‘undruggable’ target space is the primary strategic driver; TPD technologies can degrade transcription factors (MYC, BCL6), scaffolding proteins, and mutant variants of traditionally targeted proteins (ESR1-mutant estrogen receptor, AR splice variants including AR-V7) that lack druggable active sites, opening therapeutic indications completely inaccessible to conventional small molecule inhibitors.
- Restraint: PROTAC molecules' relatively large molecular weight of 700–1,200 Daltons and associated challenges in oral bioavailability, cellular permeability (requiring passive diffusion through two membranes), and tissue distribution limit the oral dosing potential of first-generation PROTACs, requiring significant medicinal chemistry investment in linker optimization and permeability enhancement to achieve drug-like properties.
- Opportunity: The May 1, 2026 FDA approval of VEPPANU (vepdegestrant) as the world's first PROTAC creates an accelerating revenue and clinical precedent effect: regulatory reviewers now have a reference framework for assessing PROTAC safety and efficacy data packages, shortening anticipated review timelines for second-generation PROTAC NDAs by an estimated 20–30% compared to the first submission.
- Trend: AI-assisted molecular glue discovery is the sector's fastest-evolving technical frontier; platforms including VantAI's structure-guided AI (deployed under its USD 674 million BMS collaboration), Monte Rosa's QuEEN chemoproteomics engine, and Kymera's computational degrader design are enabling rational design of molecular glue degraders for targets not addressable by the historically serendipitous IMiD-based discovery approach.
- Regional: North America held a 44.0% share in 2025 at approximately USD 440 million, with the United States alone contributing over 85% of North American revenue through its concentration of PROTAC-pioneering biotechs (Arvinas, Kymera, Monte Rosa, C4 Therapeutics, Nurix), major pharmaceutical TPD integrators (BMS, Pfizer, Novartis), and National Cancer Institute-funded TPD research consortia.
Key Insights Summary
- On May 1, 2026, the FDA granted approval for VEPPANU™ (vepdegestrant), developed by Arvinas, Inc. and Pfizer Inc., for adults with ESR1-mutated, ER+/HER2-negative advanced or metastatic breast cancer previously treated with endocrine-based therapy—making VEPPANU the world's first approved PROTAC protein degrader and the first degrader-specific approval in breast cancer, based on the Phase 3 VERITAC-2 trial (NCT05654623) enrolling 624 patients at 213 sites across 25 countries.
- On February 17, 2026, the FDA accepted Bristol-Myers Squibb's NDA for iberdomide (IberDd: iberdomide + daratumumab + dexamethasone) for relapsed or refractory multiple myeloma, granting Priority Review and Breakthrough Therapy Designation with a PDUFA action date of August 17, 2026; if approved, iberdomide would become the first approved CELMoD agent and potentially the first new protein degrader class in multiple myeloma treatment since pomalidomide.
- On June 25, 2025, Gilead Sciences and Kymera Therapeutics entered an exclusive option and license agreement for a CDK2-directed molecular glue degrader program (KT-200, later exercised for USD 45 million) totaling up to USD 750 million in potential payments including tiered royalties, with Kymera leading discovery activities; CDK2 molecular glue degraders remove CDK2 without inhibiting closely related CDK1, offering potentially broader therapeutic index than CDK2 small molecule inhibitors.
- In December 2025, Monte Rosa Therapeutics disclosed compelling Phase 1/2 interim data for MRT-2359, its GSPT1-directed molecular glue degrader, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer harboring androgen receptor mutations, reporting a 100% PSA response rate in 4 of 4 patients and a 100% disease control rate, with primarily Grade 1–2 adverse events—data supporting initiation of a signal-confirming Phase 2 study in 2026.
- In April 2024, Arvinas licensed its second-generation androgen receptor PROTAC ARV-766 to Novartis for USD 150 million upfront and up to USD 1.01 billion in development, regulatory, and commercial milestones, giving Novartis worldwide clinical development and commercialization rights to a Phase 3-ready candidate for metastatic castration-resistant prostate cancer that degrades both wild-type and mutant AR variants including AR-V7.
- As of 2025, approximately 80 companies globally were developing targeted protein degradation technologies, with clinical-stage activity encompassing more than 60 programs in active human studies across PROTACs (approximately half of clinical programs), next-generation CELMoD agents, and molecular glue degraders; the oncology indication pipeline is most advanced, while neurological applications including LRRK2 degradation for Parkinson's disease (Arvinas ARV-102) are entering early clinical evaluation.
Competitive Landscape Overview
The targeted protein degradation market is highly fragmented at the discovery and preclinical stage—with approximately 80 companies operating globally—but consolidating rapidly at the clinical stage around a small number of platform leaders with demonstrated ability to advance candidates through Phase 3 trials and regulatory submissions. Arvinas, Inc. holds the most differentiated position through VEPPANU's FDA approval as the world's first PROTAC, establishing Arvinas as the commercial reference for the PROTAC modality globally. Bristol-Myers Squibb occupies a unique competitive position as “the only company that has successfully developed and commercialized protein degrader agents for the treatment of multiple myeloma,” as the company describes itself, through its commercial IMiD franchise and now its advancing CELMoD pipeline.
The competitive landscape bifurcates between native TPD biotechs—including Arvinas, Kymera Therapeutics, Monte Rosa Therapeutics, C4 Therapeutics, and Nurix Therapeutics, each built from inception around a specific TPD technology platform—and major pharmaceutical companies that have integrated TPD through collaboration or acquisition, including Bristol-Myers Squibb (CELMoD platform), Novartis (Arvinas ARV-766, Monte Rosa MRT-6160, DUnad), Pfizer (vepdegestrant co-developer), Sanofi (Kymera IRAK4/STAT3 programs), Gilead Sciences (Kymera CDK2 molecular glue), and Novo Nordisk (Neomorph molecular glue platform). The pattern of multiple USD 500 million–2 billion partnerships—a total of at least six such transactions exceeding USD 500 million from 2022 through 2025—confirms that major pharmaceutical companies view TPD as a platform-level investment rather than a single-asset acquisition. The molecular glue degrader segment is attracting disproportionate deal interest relative to its current clinical maturity, reflecting pharmaceutical companies' recognition that molecular glues' smaller molecular weight and superior oral bioavailability may give them commercial pharmacokinetic advantages over first-generation PROTACs.
Competitive Landscape Matrix
| Company | HQ | Position | Key Product / Platform | Geo Strength | Recent Strategic Move |
| Arvinas, Inc. | USA (New Haven, CT) | Leader | VEPPANU™ (vepdegestrant/ARV-471) PROTAC® ER degrader; ARV-766 (AR degrader, Novartis-partnered); ARV-102 (LRRK2, neurology) | Global (co-commercialized with Pfizer) | FDA approved VEPPANU (first-ever PROTAC) on May 1, 2026 for ESR1-mutated ER+/HER2- metastatic breast cancer; ARV-766 licensed to Novartis for USD 150M upfront April 2024 |
| Bristol-Myers Squibb Company | USA (Princeton, NJ) | Leader | CELMoD™ platform: iberdomide, mezigdomide, golcadomide; IMiDs: lenalidomide, pomalidomide; ligand-directed degraders, DAC-degraders | Global | FDA accepted iberdomide NDA (IberDd) for relapsed/refractory multiple myeloma on February 17, 2026 with PDUFA date August 17, 2026; mezigdomide SUCCESSOR Phase 3 trials ongoing |
| Kymera Therapeutics, Inc. | USA (Watertown, MA) | Challenger | KT-621 (STAT3 degrader); IRAK4 degrader (Sanofi-partnered); CDK2 molecular glue (Gilead-partnered, KT-200) | N. America, Europe (partnerships) | Entered USD 750M CDK2 molecular glue option/license with Gilead on June 25, 2025; Sanofi advancing KT-485 into clinical testing; KT-621 Phase 1 data presented 2025 |
| Monte Rosa Therapeutics, Inc. | USA (Boston, MA) | Challenger | MRT-2359 (GSPT1 MGD, prostate cancer/MYC-driven tumors); MRT-6160 (VAV1 MGD, autoimmune); MRT-8102 (NEK7/NLRP3); CDK2 and CCNE1 MGD programs | N. America, Europe (Novartis, Roche partnerships) | MRT-2359 showed 100% PSA response in 4/4 AR-mutant mCRPC patients in December 2025 Phase 1 data; MRT-6160 Phase 2 advancing with Novartis collaboration |
| Pfizer Inc. | USA (New York, NY) | Challenger | Co-developer and co-commercializer of VEPPANU™ (vepdegestrant) via Arvinas collaboration | Global | Co-submitted NDA for vepdegestrant June 6, 2025; announced plan to jointly select third-party commercializer with Arvinas September 2025; co-commercializing VEPPANU following May 1, 2026 FDA approval |
| Novartis AG | Switzerland | Challenger | ARV-766 (AR-PROTAC for prostate cancer, licensed from Arvinas); MRT-6160 collaboration (Monte Rosa); DUnad collaboration | Global | Paid USD 150M upfront to Arvinas for global ARV-766 rights plus USD 1.01B potential milestones April 2024; signed second collaboration with Monte Rosa (MRT-6160) in October 2025 |
| C4 Therapeutics, Inc. | USA (Watertown, MA) | Niche Player | Cemsidomide (CC-92480 derivative for multiple myeloma, MOMENTUM Phase 2 trial); bifunctional degrader platform (TORPEDO™) | N. America | Cemsidomide entering Phase 2 MOMENTUM trial in relapsed/refractory multiple myeloma, advancing as potential competitor to BMS CELMoD agents |
| Nurix Therapeutics, Inc. | USA (San Francisco, CA) | Niche Player | Zelebrudomide (NEdd8/BTK degrader); CBL-B inhibitors; DUB inhibitor platform; DEL-based E3 ligase binder discovery | N. America | Zelebrudomide advancing in clinical evaluation for hematological malignancies; CBL-B inhibitor NX-5948 Phase 1 data supporting broader oncology applications |
By Technology Type
PROTACs (Proteolysis-Targeting Chimeras) held the largest technology share at approximately 47.7–49.0% of TPD market revenue in 2024 and are growing at an estimated 22–29% CAGR through 2034, as vepdegestrant's commercial launch as VEPPANU initiates the first PROTAC revenue stream and validates the modality for payer acceptance and prescriber adoption. PROTACs' catalytic mechanism enables a single PROTAC molecule to ubiquitinate and direct multiple copies of a target protein to the proteasome before binding the next target molecule, achieving sub-stoichiometric drug concentrations relative to target protein abundance—a pharmacodynamic property that enables high potency at potentially lower systemic exposures than equimolar inhibitors. Linker chemistry optimization is the primary active research frontier within the PROTAC segment: the ternary complex geometry between PROTAC, target protein, and E3 ligase determines ubiquitination efficiency, and AI-guided linker design is enabling systematic optimization of spatial orientation and flexibility. Arvinas' PROTAC Discovery Engine and Nurix's DNA-encoded library (DEL) approach for discovering E3 ligase binders represent distinct methodological architectures for PROTAC development, each generating proprietary intellectual property on the binder-linker-recruiter combination.
Molecular glue degraders (MGDs) are the fastest-growing technology segment, projected to expand at approximately 19.9–25.0% CAGR through 2034, driven by their superior physicochemical properties relative to PROTACs. At molecular weights below 500 Daltons, MGDs comply with Lipinski's Rule of Five for drug-likeness, enabling oral bioavailability, cellular permeability, and tissue distribution profiles comparable to conventional small molecules—properties that first-generation PROTACs at 700–1,200 Daltons frequently cannot achieve without significant formulation investment. The mechanistic logic of molecular glues also enables degradation of targets whose shallow or inaccessible surface precludes conventional ligand binding: by redirecting an E3 ligase's substrate specificity toward a neo-substrate rather than requiring the drug to bind the target protein's active site, MGDs can theoretically degrade any protein whose surface can engage a glue-modified E3 ligase interface. The field is transitioning from historically serendipitous MGD discovery—which produced IMiDs including thalidomide and lenalidomide through empirical screening without rational mechanistic design—to structure-guided rational MGD design enabled by cryo-electron microscopy determination of ternary complex structures and AI-assisted prediction of novel protein-protein interaction surfaces. Monte Rosa's QuEEN (Quantitative and Engineered Elimination of Neosubstrates) platform and VantAI's computational molecular glue design engine represent this transition in practice.
LYTACs (Lysosome-Targeting Chimeras) and AUTACs (AUtophagy-TArgeting Chimeras) represent early-stage TPD modalities primarily at the preclinical and discovery stage in 2025, addressing a distinct biological niche: extracellular proteins and membrane-anchored proteins that cannot be reached by the proteasome-directed PROTAC and MGD approaches. LYTACs redirect soluble extracellular proteins or cell-surface receptors to lysosomal degradation by bifunctional engagement of the mannose-6-phosphate receptor (CI-M6PR) or the asialoglycoprotein receptor (ASGPR) in liver-targeting applications. The LYTAC modality is particularly relevant for oncology targets including growth factor receptors and immune checkpoint proteins that are overexpressed on the cell surface, for which conventional antibody-based therapeutics have partial efficacy but no mechanism for reducing total protein expression. Carolyn Bertozzi's pioneering LYTAC work at Stanford University and its commercial translation at Lycia Therapeutics and other spinouts defines this segment's frontier.
By Therapeutic Area
Oncology dominated the targeted protein degradation market with approximately 61.4% revenue share in 2024 at approximately USD 332 million, because cancer provides the most characterized protein target landscape (hormone receptors, kinases, transcription factors, epigenetic regulators) and the most urgent clinical demand for drugs against resistance-driving mutations. The breast cancer sub-indication holds the largest share within oncology, driven by the ESR1-mutation landscape where CDK4/6 inhibitor-pretreated patients whose tumors carry ESR1 mutations face limited effective options between fulvestrant—an injectable SERD with modest efficacy in ESR1-mutated disease—and chemotherapy. Vepdegestrant's VERITAC-2 Phase 3 trial demonstrated statistically significant progression-free survival improvement versus fulvestrant specifically in ESR1-mutated patients, providing the clinical foundation for VEPPANU's approval and positioning ER-degraders as the preferred therapeutic category in this clinical context. Multiple myeloma is the second-largest oncology sub-indication, populated by an unbroken 25-year lineage of protein degrader approvals from thalidomide through lenalidomide, pomalidomide, and now advancing CELMoD agents iberdomide and mezigdomide.
Neurological disorders represent the fastest-growing therapeutic area, projected to advance at approximately 20.9% CAGR through 2032, as brain-penetrant PROTAC and molecular glue designs emerging from Arvinas (ARV-102 targeting LRRK2 for Parkinson's disease) and Monte Rosa (MRT-6160 targeting VAV1 for autoimmune neurological conditions) demonstrate early clinical feasibility of crossing the blood-brain barrier—a historically prohibitive barrier for PROTAC molecules due to their large molecular weights and potential for P-glycoprotein efflux. The Alzheimer's disease target tau (which forms neurofibrillary tangles as a driver of neurodegeneration) and the Parkinson's target LRRK2 are both amenable to PROTAC degradation strategies because their pathological forms can be distinguished from their physiological counterparts through structural recognition by carefully designed bifunctional molecules. Autoimmune and inflammatory disorders represent the third emerging area, with MRT-6160 (VAV1 degrader) demonstrating deep VAV1 elimination with no detectable off-target protein effects in Phase 1 studies, supporting therapeutic potential in T-cell and B-cell-driven immune conditions including inflammatory bowel disease, systemic lupus erythematosus, and rheumatoid arthritis.
By Application
Therapy development held the largest application segment share at approximately 56.7–57.6% of TPD market revenue in 2024 at approximately USD 305–310 million, reflecting the advanced clinical pipeline across PROTACs and CELMoD agents in oncology. Within therapy development, pharmaceutical and biotechnology companies—which together held approximately 40.8% of total end-user revenue—represent the dominant spending center because clinical development costs in Phase 1–3 trials are the primary capital outlays at the current pipeline maturity stage, and because the complex manufacturing chemistry of PROTACs and molecular glues requires specialized process chemistry investment that is distinct from conventional small molecule manufacturing. Drug discovery represents the fastest-growing application at approximately 19.75% CAGR through 2032, as computational platform companies including VantAI, Recursion Pharmaceuticals, and Insilico Medicine apply large language models and structure-prediction AI to accelerate identification of E3 ligase binder-target combinations that precede PROTAC or molecular glue candidate design. The development of PROTAC-focused contract development and manufacturing organizations (CDMOs) is supporting this growth: by February 2025, Catalent reported supporting over 25 TPD programs globally, and Recipharm announced strategic partnerships for 10 or more TPD clinical and commercial-scale programs.
Regional Analysis
North America held the largest regional share of the targeted protein degradation market in 2025 at 44.0%, generating approximately USD 440 million, anchored by the United States' concentration of TPD-focused biotechnology companies and the FDA's active regulatory science engagement with protein degrader NDAs. The U.S. market benefits from NIH funding for TPD basic science, including NCI-funded programs studying degradation of transcription factors and undruggable oncoproteins, and from private venture capital investment: the first quarter of 2024 alone saw five VC investments in TPD totaling USD 277 million, versus USD 17 million in the same period of 2023. The FDA's August 2025 NDA acceptance for vepdegestrant with Priority Review designation and Fast Track status, followed by the May 1, 2026 approval of VEPPANU, established the FDA's willingness to prioritize PROTAC review under accelerated timelines, reducing regulatory uncertainty for subsequent PROTAC NDAs. North America is projected to maintain its leadership with a CAGR of approximately 20.0% through 2034.
Europe held approximately 28.0% of TPD market revenue in 2025 at approximately USD 280 million, with the United Kingdom, Germany, Switzerland, and Belgium as the primary clinical activity centers. The UK's MHRA and the EMA's Committee for Medicinal Products for Human Use (CHMP) have both engaged with next-generation IMiD analog regulatory submissions (pomalidomide analogs for multiple myeloma) and are expected to receive MarketingAuthorization Applications for vepdegestrant and iberdomide in 2026 following their respective FDA approvals. Switzerland is disproportionately important through Novartis’ USD 150 million ARV-766 deal and Monte Rosa's second Novartis collaboration (MRT-6160), reflecting the Swiss pharma's commitment to TPD as a platform investment across oncology and immunology. The Neomorph–Novo Nordisk molecular glue deal (approximately USD 1.46 billion, signed February 2024) contributes to Europe's deal value leadership despite Neomorph being U.S.-headquartered, as Novo Nordisk's Copenhagen base drives European discovery investment.
Asia Pacific contributed approximately 20.0% of TPD market revenue in 2025 at approximately USD 200 million and is the fastest-growing region by clinical trial expansion, with China's domestic biotechs including BeiGene, Kintor Pharmaceutical, InnoCare Pharma, Kangpu Biopharmaceuticals, and CSPC advancing PROTAC candidates targeting AR, ER, and KRAS into clinical trials—creating a parallel Asia Pacific TPD clinical ecosystem that is largely independent of Western licensing. Japan and South Korea are increasing TPD investment, particularly in applications for age-related neurodegenerative diseases where their aging populations represent significant patient pools. Korea's Samsung Bioepis and Japanese CDMOs are building specialized manufacturing capabilities for bifunctional degrader chemistry, and South Korea's government-supported biotechnology programs have earmarked infrastructure for protein degrader development as a strategic national pharmaceutical priority. Latin America and the Middle East and Africa together contributed approximately 8.0% of market revenue, primarily through clinical trial site participation and eventual access to approved products including VEPPANU.
Country Analysis
The United States targeted protein degradation market reached approximately USD 390 million in 2025, growing at a country-level CAGR of approximately 21.5% through 2034. The U.S. market benefits from a uniquely dense ecosystem of TPD-native biotechs: New Haven, Connecticut hosts Arvinas; Watertown, Massachusetts hosts both Kymera Therapeutics and C4 Therapeutics; Boston hosts Monte Rosa Therapeutics; and San Francisco hosts Nurix Therapeutics and other platform companies—a geographic concentration that facilitates talent exchange, academic collaboration with Harvard, MIT, Dana-Farber Cancer Institute, and Yale, and venture capital clustering. The FDA's Oncology Center of Excellence has engaged directly with PROTAC regulatory science through its Project Optimus initiative on dose optimization, which is particularly relevant to PROTACs where the hook effect (reduced degradation at excessively high concentrations due to formation of binary rather than ternary complexes) creates non-monotonic dose-response relationships that require specialized trial design. The FDA accepted both the NDA for vepdegestrant (August 8, 2025) and the NDA for iberdomide (February 17, 2026) with Priority Review—demonstrating an acceleration of TPD regulatory processing that directly benefits the commercial timelines of second-generation PROTAC and CELMoD programs in the pipeline.
The United Kingdom's TPD market reached approximately USD 48 million in 2025, growing at an estimated 18.5% CAGR. The UK hosts significant TPD discovery infrastructure at Oxford University (where Alessio Ciulli's laboratory pioneered PROTAC BET bromodomain chemistry), Cambridge (where the MRC Laboratory of Molecular Biology advances ubiquitin biology) and at Dundee University's Centre for Targeted Protein Degradation—which has produced numerous academic spinouts including Amphista Therapeutics, which was acquired by AstraZeneca in 2022. AstraZeneca's Cambridge headquarters makes it the UK's most significant TPD-integrated pharmaceutical company, with multiple internal PROTAC discovery programs targeting KRAS, EGFR, and oncology kinases. The MHRA's early engagement with next-generation IMiD analog regulatory science positions the UK for rapid MRA processing of forthcoming CELMoD and PROTAC submissions. China's TPD market reached approximately USD 88 million in 2025, growing at an estimated 24.5% CAGR—the highest single-country growth rate in the sector—driven by domestic biotech pipeline expansion. China's NMPA (National Medical Products Administration) is actively engaged with PROTAC IND applications from BeiGene, Kintor Pharmaceutical, and other Chinese biotechs that are advancing domestically developed PROTAC candidates through Phase 1/2 trials in Chinese patient populations, positioning China as both a clinical trial site for global programs and an independent innovation center for the sector.
Switzerland's TPD market reached approximately USD 38 million in 2025, disproportionately large relative to its healthcare market size due to Novartis's positioning as the single most active major pharmaceutical investor in next-generation TPD partnerships. Novartis's ARV-766 deal (USD 150M upfront + USD 1.01B potential), its MRT-6160 collaboration with Monte Rosa (second collaboration signed October 2025), and its earlier USD 1.3 billion alliance with Dunad Therapeutics collectively make Novartis the largest capital deployer in TPD partnerships among traditional pharmaceutical companies—a strategy reflecting the company's conviction that TPD will enable treatment of the androgen receptor-driven and immune-mediated disease areas that Novartis has historically prioritized. Germany's TPD market reached approximately USD 32 million in 2025, growing at approximately 17.5% CAGR, anchored by Merck KGaA's degrader-antibody conjugate (DAC) program and its University of Leipzig collaboration, and by Bayer AG's Arvinas collaboration for hormone-driven cancer PROTACs established in prior years.
Targeted Protein Degradation Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
21.0%
The Forecast Market
Size for 2034 in USD:
$USD 5.56 B
Get more details on this report -
Key Market Segment
By Technology Type
- PROTACs (Proteolysis Targeting Chimeras)
- Molecular Glues
- Lysosome Targeting Chimeras (LYTACs)
- Others
By Therapeutic Area
- Oncology
- Neurological Disorders
- Autoimmune Diseases
- Others
By Application
- Drug Discovery
- Clinical Therapeutics
- Research Applications
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 1.00 B |
| Forecast Revenue (2034) | USD 5.56 B |
| CAGR (2025-2034) | 21.0% |
| Historical data | 2021-2025 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Technology Type, (PROTACs (Proteolysis Targeting Chimeras), Molecular Glues, Lysosome Targeting Chimeras (LYTACs), Others), By Therapeutic Area, (Oncology, Neurological Disorders, Autoimmune Diseases, Others), By Application, (Drug Discovery, Clinical Therapeutics, Research Applications, Others), |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | ARVINAS, INC., BRISTOL-MYERS SQUIBB COMPANY, KYMERA THERAPEUTICS, INC., MONTE ROSA THERAPEUTICS, INC., PFIZER INC., NOVARTIS AG, C4 THERAPEUTICS, INC., NURIX THERAPEUTICS, INC., ASTRAZENECA PLC, BAYER AG, SANOFI S.A., GILEAD SCIENCES, INC., ROCHE HOLDING AG, NOVO NORDISK A/S, VANTAI, INC., FRONTIER MEDICINES CORPORATION, NEOMORPH INC., LYCIA THERAPEUTICS, INC., PROXYGEN GMBH, OTHERS |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Targeted Protein Degradation Market?
Global Targeted Protein Degradation Market was valued at USD 0.83 billion in 2024 and is projected to reach USD 5.56 billion by 2034, at a CAGR of 21.0% during 2026–2034.
Who are the major players in the Targeted Protein Degradation Market?
ARVINAS, INC., BRISTOL-MYERS SQUIBB COMPANY, KYMERA THERAPEUTICS, INC., MONTE ROSA THERAPEUTICS, INC., PFIZER INC., NOVARTIS AG, C4 THERAPEUTICS, INC., NURIX THERAPEUTICS, INC., ASTRAZENECA PLC, BAYER AG, SANOFI S.A., GILEAD SCIENCES, INC., ROCHE HOLDING AG, NOVO NORDISK A/S, VANTAI, INC., FRONTIER MEDICINES CORPORATION, NEOMORPH INC., LYCIA THERAPEUTICS, INC., PROXYGEN GMBH, OTHERS
Which segments covered the Targeted Protein Degradation Market?
By Technology Type, (PROTACs (Proteolysis Targeting Chimeras), Molecular Glues, Lysosome Targeting Chimeras (LYTACs), Others), By Therapeutic Area, (Oncology, Neurological Disorders, Autoimmune Diseases, Others), By Application, (Drug Discovery, Clinical Therapeutics, Research Applications, Others),
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Targeted Protein Degradation Market
Published Date : 18 Jul 2026 | Formats :Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date